What is Immunophotonics?
Headquartered in St. Louis with a global footprint in Switzerland and China, Immunophotonics operates at the intersection of oncology and immunology. The company is pioneering a novel approach to cancer treatment by transforming localized tumor destruction into a systemic immune response. This mechanism of action is designed to address the limitations of current solid tumor therapies, positioning the firm as a high-potential player in the immuno-oncology landscape. With its phase 2 development status, the company is transitioning from early-stage research into a more mature clinical entity, supported by a robust intellectual property portfolio and a strategic network of institutional and private investors.
How much funding has Immunophotonics raised?
Immunophotonics has raised a total of $26.3M across 5 funding rounds:
Private Equity
$550K
Private Equity
$2.5M
Series A
$1.8M
Debt
$111K
Series B
$21.4M
Private Equity (2010): $550K, investors not publicly disclosed
Private Equity (2014): $2.5M led by BioGenerator and Cultivation Capital
Series A (2014): $1.8M supported by Missouri Technology, St Louis Arch Angels, BioGenerator, Cultivation Capital, and Billiken Angels Network
Debt (2021): $111K featuring PPP
Series B (2022): $21.4M backed by Zubizoom and AC Immune
Key Investors in Immunophotonics
BioGenerator
Based in St. Louis, Missouri, BioGenerator creates and grows innovative companies through its two complementary approaches, investing through BioGenerator Ventures and comprehensive startup support through BioGenerator Labs.
Cultivation Capital
Cultivation Capital is a venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences, software, agriculture, and geospatial technology.
Zubizoom
Zubizoom LLC is a family investment platform focusing on various investment opportunities across multiple sectors, including significant financial backing for innovative growth-stage companies.
What's next for Immunophotonics?
The recent influx of capital is expected to accelerate the clinical validation of IP-001, providing the necessary runway to navigate complex regulatory environments and expand trial sites. As the company moves deeper into phase 2, the focus will likely shift toward optimizing manufacturing processes and preparing for potential late-stage clinical milestones. Given the firm's unique positioning in interventional oncology, future strategic efforts will likely involve exploring synergistic partnerships with larger pharmaceutical entities or pursuing further capital rounds to support large-scale phase 3 trials, ultimately aiming to bring this transformative therapy to a broader patient population.
See full Immunophotonics company page
